Literature DB >> 10702571

Primary resistance to flucytosine among clinical isolates of Candida spp.

F Barchiesi, D Arzeni, F Caselli, G Scalise.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10702571     DOI： 10.1093/jac/45.3.408

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  12 in total

1.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.

Authors:  M A Pfaller; S A Messer; L Boyken; H Huynh; R J Hollis; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Authors:  M A Pfaller; A Espinel-Ingroff; E Canton; M Castanheira; M Cuenca-Estrella; D J Diekema; A Fothergill; J Fuller; M Ghannoum; R N Jones; S R Lockhart; E Martin-Mazuelos; M S C Melhem; L Ostrosky-Zeichner; P Pappas; T Pelaez; J Peman; J Rex; M W Szeszs
Journal:  J Clin Microbiol       Date:  2012-03-29       Impact factor: 5.948

5.  Molecular mechanisms of primary resistance to flucytosine in Candida albicans.

Authors:  William W Hope; Lydia Tabernero; David W Denning; Michael J Anderson
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

7.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 8.  Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.

Authors:  Konstantin A Demin; Aleksandr G Refeld; Anna A Bogdanova; Evgenya V Prazdnova; Igor V Popov; Olga Yu Kutsevalova; Alexey M Ermakov; Anzhelica B Bren; Dmitry V Rudoy; Vladimir A Chistyakov; Richard Weeks; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-18       Impact factor: 4.609

9.  Clinical efficacy and health implications of inconsistency in different production batches of antimycotic drugs in a developing country.

Authors:  Adenike A O Ogunshe; Adedayo A Adepoju; Modupe E Oladimeji
Journal:  J Pharm Bioallied Sci       Date:  2011-01

10.  Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates.

Authors:  Kari-Mette Andersen; Anne Karin Kristoffersen; André Ingebretsen; Katharina Johnsen Vikholt; Ulf Thore Örtengren; Ingar Olsen; Morten Enersen; Peter Gaustad
Journal:  J Oral Microbiol       Date:  2016-02-08       Impact factor: 5.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.